Wire · founder news, decoded · opportunities
How BMS is Using NVIDIA AI to Discover New Drugs | AI Magazine
◆ Published
22 July 2026
◆ Topic
opportunities
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 July 2026 · Fusion42 review
Bristol Myers Squibb is deploying NVIDIA DGX SuperPOD infrastructure with 10x greater performance per megawatt to accelerate AI-driven drug discovery, supported by a strategic partnership with Anthropic to embed Claude agents across R&D, clinical development and manufacturing workflows.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ The Wire takeaway
If you sell to pharma R&D—molecule design tools, data integration, lab automation—BMS just proved the market will buy AI at industrial scale and embed it into core discovery loops. Your customer now has Claude agents and Vera Rubin compute as the baseline; you're competing against that or becoming a layer on top of it.
◆ Related on Wire
- BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's.21 July 2026
- Bora inks $2.5B deal with drug discovery AI specialist Insilico16 July 2026
- Aureka Launches Free AI Drug Discovery Model8 July 2026
- Anthropic wants to disrupt drug discovery. Industry experts say the real challenge co | Ctech12 July 2026
- Insilico Medicine Deepens AI Drug Discovery Tie-Up With Tencent Health20 July 2026
- AI data becomes sticking point in biopharma dealmaking22 July 2026
◆ Topics
Digital Health · drug-discovery · ai-infrastructure · compute-scaling · biotech-automation · nvidia-deployment